Protective Effect of Melatonin on Carbon Tetrachloride-induced Hepatic Fibrogenesis in Rats

Mona F. El-Karn
Medical Physiology Department, Faculty of Medicine, Assiut University

ABSTRACT

Background: Liver cirrhosis is a critical stage of chronic liver diseases that can produce liver failure, portal hypertension and hepatic carcinoma. Sustained oxidative stress plays a key role in cell damage and fibrosis induced during liver cirrhosis. Aim of the work: The aim of the present study was to examine the potential protective effect of exogenous melatonin co-treatment on liver tissue injury and oxidative stress processes during induction of early phase of liver fibrosis by carbon tetrachloride (CCl4) injection in rats. Methods: Hepatic fibrogenesis model was induced in this study by subcutaneous injection of rats by carbon tetrachloride (CCl4). Eighteen adult, female albino rats were randomly divided into 3 groups (n = 6): control group (group I), carbon tetrachloride treated group (group II) and CCl4 + melatonin co-treated group (group III). Rats in CCl4 treated group were injected subcutaneously with sterile CCl4 (2 ml/kg of body weight) in a ratio of 1:1 with olive oil twice a week for 8 weeks. Rats of group III (melatonin co-treated group) were injected with CCl4 in the same manner as in group II and received intraperitoneal melatonin injection in a dose of 20 mg/kg twice a week for 8 weeks, starting from the beginning of CCl4 injection. Rats in normal control group were injected subcutaneously with olive oil at the same dose and frequency as those in CCl4 treated group. At the end of the experiment, rats were sacrificed, blood samples were collected for biochemical assay. Liver from each animal was removed for histopathological examination. Measurement of oxidative stress markers in serum was done by chemical estimation of serum levels of free radicals: lipid peroxides (LPO) and nitric oxide (NO). Antioxidant enzymes were estimated by chemical measurement of glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) in the serum. Liver injury was assessed by evaluation of serum levels of liver enzymes (alanine aminotransferase (ALT), and aspartate aminotransferase (AST)). Determination of development of early phase of hepatic fibrogenesis was done by chemical measurement of serum level of hyaluronic acid (HA) using enzyme immunoassay (ELISA), and by histopathological examinations of hepatic tissues to detect early fibrotic changes as well as other histological damage of hepatic tissue caused by CCl4 injection with or without melatonin administration. Results: Results of the present study showed that CCl4 treatment to rats of group II caused highly significant increase in serum levels of oxidative stress markers (lipid peroxides and nitric oxide), decrease in serum levels of antioxidant markers (glutathione peroxidase and superoxide dismutase), increase of serum levels of hepatic enzymes (ALT and AST) as well as increased serum level of hyaluronic acid (HA) 8 weeks after CCl4 injections when compared with control group. Melatonin co-treatment to animals of group III caused significant reduction in...
serum levels of lipid peroxides (LPS) and nitric oxide (NO), significant increase in plasma levels of glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD), significant reduction in serum levels of liver enzymes (ALT and AST) as well as significant decrease in serum level of hyaluronic acid (HA) 8 weeks after CCl₄ injections when compared with group II. Histopathological study of liver tissue of animals of CCl₄ treated group showed various manifestation of hepatic cell damage and early phase of fibrogenesis as necrosis, degeneration, collagen deposition and few fibrous threads extending into the hepatic lobules. Histopathological study of hepatic tissue of melatonin co-treated group showed that melatonin caused marked amelioration of histological manifestations of hepatic cell degeneration and absence of any sign of fibrogenesis with nearly normalization of the histological appearance of the hepatic tissue. Compared with CCl₄ treated group (group II), histological appearance of hepatic tissue of rats in melatonin co-treated group (group III) showed significant improvement. Conclusion: Results of this study suggest that melatonin has a substantial hepatoprotective effect in a rat hepatic fibrosis model induced by an 8-weeks’ CCl₄ regimen. The protective effect of melatonin may be due to both its direct radical scavenging properties and indirect effect as a regulator of antioxidant systems. Therefore, the study proposes that melatonin may be a valuable drug for inhibition of unwanted fibrosis in patients exposed to different hepatotoxic agents.

INTRODUCTION

Liver diseases have a variety of causes such as infections, parasites, nutrition deficiency, inborn errors, toxic substances and malignancy. Viral hepatitis is the major cause of liver disease in tropical areas including Egypt¹. Liver fibrosis results from sustained activation of hepatic stellate cells (HSC) by oxidative stress and cytokines. It replaces damaged cells with an extracellular matrix (²). If treated properly at fibrosis stage, cirrhosis can be prevented (³). Liver cirrhosis is a critical stage of chronic liver diseases that can produce liver failure, portal hypertension and hepatocarcinoma. It is related to high morbidity/mortality rate. The induction of oxidative stress, mitochondrial dysfunction and depletion of antioxidant status is a relevant feature in the progression of liver cirrhosis and fibrosis (⁴,⁵). The current treatments of liver cirrhosis are limited to the removal of the underlying injurious stimulus, e.g. viruses in cases involving viral hepatitis. However, no effective antifibrosis drugs are available at present (⁶). Carbon tetrachloride (CCl₄) is widely used to induce hepatic fibrosis and cirrhosis in animal models (⁷). In the past years, carbon tetrachloride was widely used as a dry cleaning solvent until it was recognized as a carcinogen. Today, it is primarily used as an organic solvent and thousands of workers are potentially exposed to this chemical (⁸). Oxidative stress, free radical generation and lipid peroxidation have been postulated to participate in the molecular mechanism of CCl₄ induced hepatotoxicity (⁹). Liver cell injury induced by carbon tetrachloride involves initially the metabolism of carbon tetrachloride to
trichloromethyl free-radical by the mixed function oxidase system of the endoplasmic reticulum\textsuperscript{10}. This trichloromethyl free radical (CCl\textsubscript{3}), reacts rapidly with molecular oxygen to produce the trichloromethyl peroxyl radical (CCl\textsubscript{3}O\textsubscript{2}) and that these highly toxic radicals are responsible for attacks on unsaturated fatty acids of phospholipids present in the cell membrane, leading to lipid peroxidation in the liver cells\textsuperscript{11}. In this regard, the reduction of oxidative stress may be a useful approach to reduce cell injury, cirrhosis and fibrosis induced by CCl\textsubscript{4} in experimental models of liver fibrosis \textsuperscript{12,13}. Many reports indicate that CCl\textsubscript{4} causes necrosis, fibrosis, mononuclear cell infiltration, steatosis and foamy degeneration of hepatocytes, increase in mitotic activity and cirrhosis in the liver\textsuperscript{14,15,16}. CCl\textsubscript{4} has also been reported to cause apoptosis in liver cells\textsuperscript{15,17,18,19}.

Several lines of evidence suggest that oxidative stress plays an important role in the etiopathogenesis of hepatic fibrosis \textsuperscript{18,20}. In attempting to limit the oxidative damage effect on hepatic cells, a number of antioxidants have been tested in experimental hepatic fibrosis models \textsuperscript{22}. Melatonin (N-acetyl-5-methoxy-tryptamine), a lipophilic indoleamine derived from tryptophan, was long thought to be produced exclusively in the pineal gland, but it has recently been detected in many other tissues. It regulates circadian rhythms, sleep and immune system activity, and behaves as a free radical scavenger \textsuperscript{29}. It also exerts cytoprotection in various experimental models of liver injury \textsuperscript{24,25}. Melatonin has been proved to have the greatest impact not only on oxidative stress, but also on systems of defense against free radicals, restoring the oxidative balance in treated experimental animals \textsuperscript{22,26}.

**Aim of the work:**

The aim of the present study was to examine the potential protective effect of exogenous melatonin co-treatment on liver tissue injury and oxidative stress processes during induction of early phase of liver fibrosis by carbon tetrachloride (CCl\textsubscript{4}) injection in rats. Therefore, the current study investigated the changes in oxidative processes, liver enzymes and serum marker of fibrosis with or without melatonin administration to CCl\textsubscript{4} treated rats. Additionally, a detailed histopathological examination of hepatic tissues of all rat groups was performed to study effect of melatonin administration on histological damage caused by CCl\textsubscript{4} injection.

**MATERIALS & METHODS**

**Reagents:**

Nacetyl-5-methoxytryptamine (melatonin) was purchased from Sigma-Aldrich GmbH, Germany. Carbon tetrachloride (CCl\textsubscript{4}) obtained from El-Gomhorya Company, Cairo, Egypt. Kits for Hyaluronic Acid (HA) was supplied by New Test Company, Cairo, Egypt. Kits for Hyaluronic Acid (HA) test kit \textsuperscript{27}. All other reagents were of analytical grade.

**Animals:**

Eighteen adult, female albino rats weighing 160-200 gram were obtained from the Animal House of Faculty of Medicine of Assiut University. Rats were housed in groups in temperature and humidity regulated room, with
free access to food and water. They were randomly divided into 3 groups \( (n = 6) \): control group (group I), carbon tetrachloride (CCl\(_4\)) treated group (group II) and CCl\(_4\) + melatonin co-treated group (group III). Rats in CCl\(_4\) treatment groups were injected subcutaneously with sterile CCl\(_4\) (2 ml/kg of body weight) in a ratio of 1:1 with olive oil twice a week for 8 weeks. Rats of group III injected with CCl\(_4\) in the same manner as in group II and received intraperitoneal melatonin injection in a dose of 20 mg/kg twice a week for 8 weeks, starting from the beginning of CCl\(_4\) injection. Rats in normal control group subcutaneously injected with saline and olive oil (in a ratio of 1:1) at the same dose and frequency as those in CCl\(_4\) treated group.

After 8 weeks, all animals were sacrificed. An immediate laparotomy was performed for each animal in all groups. Blood was drawn from the abdominal aorta and livers were removed from all animals. Blood was collected into tubes and centrifuged. Serum was aspirated and frozen at –20 ºC until time of biochemical assay. Liver tissue was fixed in formalin and embedded in paraffin. Thin sections of hepatic tissues were obtained for histopathological evaluation of the damage caused by CCl\(_4\) injection with or without melatonin administration.

(A) **Biochemical determination:**

1. **Measurement of oxidative stress markers in serum:**
   This was done by estimation of serum levels of free radicals: lipid peroxides (LPO) and nitric oxide (NO):
   - **Determination of serum level of lipid peroxides (LPO):** Serum level of lipid peroxides (LPO) was measured as thiobarbituric acid reactivity (TBARS). The product of the reaction between malondialdehyde and thiobarbituric acid was measured as described by Thayer (1985)(28).
   - **Nitric oxide (NO) level in the serum** was determined by the method of Van Bezooijen et al. (1998)(29).

2. **Measurement of antioxidant markers in serum:**
   This was done by estimation of serum levels of antioxidant enzymes: glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD):
   - **Serum glutathione peroxidase (GSH-Px) level in the serum** was determined chemically as described by Ellman (1959)(30).
   - **Superoxide dismutase (SOD) level in the serum** was determined according to the method of Misra and Fridovich (1972)(31).

3. **Analysis of liver enzymes:**
   Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured with routine laboratory methods by kinetic method (Breuer J, 1996)(32).

4. **Measurement of serum hyaluronic acid (HA):**
   Estimation of serum Hyaluronic Acid (HA) by enzyme immunoassay (EIA) using Hyaluronic Acid (HA) Test Kit as described by Guechot et al. (2000)(27).

(B) **Histopathological examination:**
   All sections of liver tissues were stained with Hematoxylin and Eosin (H&E) according to Drury and Wallington (1980)(33) for detection of
histological manifestations of hepatic cell damage as well as detection of early fibrogenesis caused by CCl₄ injection with or without melatonin administration.

**Statistical analysis:**
Simple descriptive statistical tests; Mean ± Standard Error (SE) were used to describe the numerical values of the sample. Student t-test was used to compare between two groups. Sperman correlation test was also used with a range from –1 to 1. A difference was considered significant at probability of p <0.05, highly significant at p<0.01 and very highly significant at p<0.001.

**RESULTS**

**Effect of melatonin administration on oxidative stress markers after CCl₄ injection:**
CCl₄ treated group (group II) showed marked increase in serum levels of oxidative stress markers as reflected by a highly significant increase in mean values of lipid peroxides and nitric oxide (p<0.001 for each), 8 weeks after CCl₄ injection when compared with control group (group I). Melatonin co-treatment to animals of group III caused significant reduction in serum levels of lipid peroxides and nitric oxide (p<0.001 and <0.01 for each parameter respectively) when compared by group II (p<0.001 for each). Comparing results of melatonin co-treatment group (group III) with those of control one showed non significant difference (p>0.05) for LPO level, at the same time, NO serum level still showing significant increase (p<0.05) when compared to level of control group (Table I).

**Effect of melatonin administration on antioxidant markers after CCl₄ injection:**
CCl₄ treated group (group II) showed a very highly significant reduction in antioxidant markers as serum levels of GSH-Px and superoxide dismutase (p<0.001 for each), 8 weeks after CCl₄ injection when compared with control group (group I). Melatonin co-administration to animals of group III caused a significant increase in plasma levels of glutathione peroxidase (GSH-Px) and superoxide dismutase when compared by group II (p<0.001 for each). Comparing results of melatonin treatment group (group III) with those of control one showed non significant difference (p>0.05) for GSH-Px level, at the same time, SOD serum level still showing significant decrease (p<0.05) comparing to levels of control group (Table 2).

**Effect of melatonin administration on liver enzymes after CCl₄ injection:**
Estimation of serum level of hepatic enzymes (ALT and AST) showed very highly significant increase (p<0.001 for each) in mean serum level of ALT and AST in CCl₄ treated group (group II) as compared with the control group. Melatonin co-treatment to animals of group III caused significant reduction in ALT and AST enzymes when compared by group II (p<0.001 for each). Melatonin co-treated group still showing significant increased liver enzymes (p<0.05) as compared to control group (Table 3).
Effect of melatonin administration on serum level of hyaluronic acid (HA) after CCl₄ injection:

Measurement of serum HA showed significantly higher level in CCl₄ treated group (group II) than in normal control group (P<0.001). Melatonin co-treatment to animals of group III caused a significant reduction in serum level of HA (p<0.001) when compared by group II. Also, rats of group III showed non significant increase (p>0.05) in serum level of HA as compared with that of the control group (Graph 1). Also, Table (4) showed very highly significant positive correlation between HA and liver enzymes (ALT&AST) (P<0.001).

Effect of melatonin administration on histopathological changes of hepatic tissues caused by CCl₄ injection:

At the end of the experiment, liver tissue samples from control rats (group I) showed normal lobular architecture with central veins and radiating hepatic cords (Figure 1). Liver tissue samples from group II (CCl₄ treated group) showed hepatic cell degeneration, necrosis, collagen deposition and venous engorgement in the microcirculatory bed. Scattered fibrous threads appear every now and then in-between hepatic lobules (Figure 2). In group III (CCl₄ + melatonin treated group) however, hepatocyte degeneration, necrosis and infiltration of inflammatory cells were all apparently ameliorated. Collagen deposition was also markedly reduced with no apparently formed fibrous threads with normalization of the appearance of the microvascular bed (Figures 3). Compared with group II, the histological picture of the liver tissue of rats in melatonin co-treated group was significantly improved.

Table (1): Effect of melatonin co-treatment on serum level of oxidative stress markers (LPO&NO) (µmol/L) in CCL4 treated rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>n</th>
<th>LPO (µmol/L)</th>
<th>NO (µmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>6</td>
<td>4.83±0.231</td>
<td>5.64±0.167</td>
</tr>
<tr>
<td>Group II</td>
<td>6</td>
<td>13.61±0.876</td>
<td>9.32±0.345</td>
</tr>
<tr>
<td>P1</td>
<td></td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>P2</td>
<td></td>
<td>***</td>
<td>**</td>
</tr>
<tr>
<td>Group III</td>
<td>6</td>
<td>6.02±0.088</td>
<td>7.08±0.187</td>
</tr>
<tr>
<td>P3</td>
<td></td>
<td>ns</td>
<td>*</td>
</tr>
</tbody>
</table>

Values are Mean ± SE (Standard error) n= number of rats. LPO: lipid peroxides NO: nitric oxide

Group (I): control group Group (II): CCl₄ treated group (III): CCl₄ + melatonin co-treatment group

P1: significant as compared group II to group I by t-test P2: significant as compared group III to group II by t-test. P3: significant as compared group III to group I by t-test. ns: non significant (p>0.05). (*): significant at 0.05. (**:): Highly significant at 0.01. (**): Very highly-significant at 0.001.

238
Table 2: Effect of melatonin co-treatment on serum levels of antioxidant enzymes (GSH-Px & SOD) (µmol/L) in CCl₄ treated rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>N</th>
<th>GSH-Px</th>
<th>S.O.D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>6</td>
<td>4.26±0.189</td>
<td>5.82±0.207</td>
</tr>
<tr>
<td>Group II</td>
<td>6</td>
<td>1.72±0.089</td>
<td>1.13±0.065</td>
</tr>
<tr>
<td>P1</td>
<td></td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>P2</td>
<td></td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Group III</td>
<td>6</td>
<td>4.06±0.207</td>
<td>4.32±0.199</td>
</tr>
<tr>
<td>P3</td>
<td></td>
<td>ns</td>
<td>*</td>
</tr>
</tbody>
</table>

Values are Mean ± SE (Standard error) n= number of rats.
GSH-Px: Glutathione peroxidase S.O.D: Superoxide dismutase

Group (I): control group
Group (II): CCL₄ treated group
Group (III): CCL₄ + melatonin co-treatment group
P1: significant as compared group II to group I by t-test
P2: significant as compared group III to group II by t-test.
P3: significant as compared group III to group I by t-test.
ns: non significant (p>0.05).
(*): significant at 0.05.  (**): Very highly-significant at 0.001.

Table 3: Effect of melatonin co-treatment on serum levels of liver enzymes (ALT & AST) (U/L) in CCl₄ treated rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>n</th>
<th>ALT</th>
<th>AST</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>6</td>
<td>37.38±2.351</td>
<td>5.60±0.476</td>
</tr>
<tr>
<td>Group II</td>
<td>6</td>
<td>157.97±0.345</td>
<td>7.83±0.307</td>
</tr>
<tr>
<td>P1</td>
<td></td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>P2</td>
<td></td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Group III</td>
<td>6</td>
<td>61.34±4.155</td>
<td>6.42±0.215</td>
</tr>
<tr>
<td>P3</td>
<td></td>
<td>*</td>
<td>*</td>
</tr>
</tbody>
</table>

Values are Mean ± SE (Standard error) n= number of rats.
ALT: alanin aminotransferase AST: aspartate aminotransferase

Group (I): control group
Group (II): CCL₄ treated group
Group (III): CCL₄ + melatonin co-treatment group
P1: significant as compared group II to group I by t-test
P2: significant as compared group II to group III by t-test.
P3: significant as compared group III to group I by t-test.
(*): significant at 0.05.  (**): Very highly-significant at 0.001.

Table 4: Correlation between hyaluronic acid and liver enzymes (ALT&AST)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Hyaluronic acid</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT</td>
<td>0.973</td>
</tr>
<tr>
<td>AST</td>
<td>0.975</td>
</tr>
</tbody>
</table>

(**): Very highly-significant at 0.001 (by Sperman correlation test).
ALT: alanin aminotransferase  AST: aspartate aminotransferase
Graph (1): Serum Hyaluronic acid (ng/ml) of the studied groups

Figure (1): Light microscopic picture of liver tissue from rat of group (I) showing normal histological picture of control rat (H&E x 400).

Figure (2): Light microscopic picture of liver tissue from rat of group (II) showing histopathological changes induced by CCl₄ injection (H&E x 400).
DISCUSSION

Hepatic fibrosis is a progressive pathological process involving multiple cellular and molecular events that lead ultimately to the accumulation of collagen and extra cellular matrix proteins in the space of Disse. Chronic injury leading to fibrosis in the liver occurs in response to a variety of insults, including viral infection, tissue-immune mediated damage, toxic agents, obstructive jaundice, gene abnormalities, or alcohol and nonalcohol steatohepatitis. When this injury process is combined with ineffective regeneration and repair, there is increasing distortion of the normal liver architecture, and the end result is cirrhosis \(^{34,35}\). Current evidence indicates that hepatic fibrosis even cirrhosis is dynamic and can be bi-directional (involving phases of progression and regression) \(^{36}\). The induction of oxidative stress is a key feature in the destruction of parenchyma and the activation of stellate cells that leads to liver cirrhosis and fibrosis \(^{37}\).

CCL\(_4\) is commonly used for inducing liver fibrosis in experimental animals. It has been reported that CCL\(_4\) damages liver mitochondria by inhibition of cytochrome oxidase and by enhanced oxidative stress. Lipid peroxidation is considered to be the most important mechanism in the pathogenesis of liver damage induced by CCL\(_4\) \(^{38}\). One mechanism of the tissue-damaging effects of CCL\(_4\) is considered to include the generation of trichloromethyl (CCL\(_3\)) and trichloromethylperoxyl (CCL\(_3\)O\(_2\)) radicals and covalent binding of CCL\(_3\) to membrane proteins and lipids. These radicals can accept protons from unsaturated fatty acid molecules of membrane lipids resulting in the initiation of LPO processes and loss of membrane enzymes \(^{11}\).

Melatonin has been reported to reduce damage to hepatic tissues after CCL\(_4\) intoxication \(^{39}\). In many studies, hepatic fibrosis was successfully induced by subcutaneous injection of sterile CCL\(_4\). Through this hepatic fibrosis model, the effects of melatonin on hepatic fibrosis induced by CCL\(_4\) in rats were examined \(^{7}\).
In the present study, subcutaneous injection of rats of group II with CCl₄ (2 ml/kg of body weight, twice a week for 8 weeks) resulted in a significant increase in serum level of oxidative stress markers as indicated by increased serum level of lipid peroxides (LPO) and nitric oxide (NO). This was consistent with the findings of other investigators (14,40,41,19). In 2002, Drewa et al. (37) reported an increase in serum level of malondialdehyde (MDA), the main product of lipid peroxidation and its concentration is generally presented as the total level of lipid peroxidation products. As an end product of lipid peroxidation, MDA can produce ozone, which reacts rapidly with cellular structures, generates hydrogen peroxide and other reactive oxygen species, leading to peroxidation and denaturation of membranes (42). Also, significant increases in NO serum level have been observed in group II as compared to that of its control values. This was in agreement with the finding of Wu et al. (2007) and Wang et al. (2007) (19,41) which indicate that CCl₄ had disrupted the antioxidant defense mechanisms causing oxidative damage of hepatic cells.

A number of antioxidants have been tested in experimental liver fibrosis models in attempts to limit the oxidative damage (22). In the current study administration of melatonin (20 mg/kg twice a week for 8 weeks from the beginning of CCl₄ injection) to rats of group III (CCl₄ + Melatonin group) induced significant reduction of mean serum levels of LPO and NO levels. Additionally, significant increase in mean serum levels of both GSH-Px and SOD has been revealed in comparison with group II. These findings indicate that melatonin co-treatment with CCl₄ could decrease lipid peroxidation and free radical formation and lead to a substantial recovery of the major antioxidant enzymes, thus limiting oxidative damage to the liver and could be considered as a protective agent against liver injury. These results were in agreement with previous studies which recorded significant reduction of oxidative stress markers with marked increase in antioxidant levels after melatonin treatment in cases of hepatic intoxication (22,43). In 2004, Tahan et al. (44) found that melatonin can restore GSH-Px activity in a rat liver fibrosis model. Hepatic GSH is known to play an important role in protecting livers against injury in rats treated with CCl₄ (45). Also, melatonin administration prevented CCl₄-induced NO generation. This may be due to the scavenging of NO by that of its control values. This was in agreement with the finding of Wu et al. (2007) and Wang et al. (2007) (19,41) which indicate that CCl₄ had disrupted the antioxidant defense mechanisms causing oxidative damage of hepatic cells.
melatonin and the ability of this indole to inhibit nitric oxide synthase\(^{46}\).

The mechanisms of the regulatory and protective effects of melatonin have been extensively studied in recent years. The beneficial properties of melatonin include its amphiphilicity and limited toxicity even at high pharmacological concentrations \(^{47,18}\). Melatonin protects DNA, proteins, and biological membrane lipids from the deleterious effects of free radicals, without the need for a specific receptor on the cells \(^{48}\).

In general, melatonin has properties of both a direct and indirect antioxidant agent. In 2000, Liu et al.\(^{49}\) reported that melatonin is not only a direct antioxidant but also an indirect antioxidant through enhancement of antioxidant enzyme activities in liver. Although the activity of melatonin is in part related to its direct antioxidant effect (through direct scavenger of free radicals), there are several studies suggesting that its activity might be associated with an indirect antioxidant activity by influencing gene expression and regulation of antioxidant enzymes \(^{50,51}\).

Melatonin also has been reported to stimulate the activities of enzymes and increase gene expression that improves the total antioxidative defense capacity of the organism, i.e., SOD, glutathione peroxidase, and glutathione reductase\(^{52,53,54}\). Moreover, recent studies indicate that melatonin is effective in inhibiting oxidative liver damage. This effect may be due to the positive transcriptional activation of melatonin in several antioxidant-related genes\(^{54}\).

The protective actions of melatonin may be due to the molecule itself and to its metabolites. The efficacy of melatonin in reducing oxidative stress is increased by the metabolites that produces while scavenging, i.e. cyclic 3-hydroxy-melatonin (cyclic 3-OHM), N-acetyl-N2-formyl-5-methoxykuramine (AFMK), and N1-acetyl-5-methoxykuramine (AFM), which also appear to be efficient scavengers. Thus, second and third generation metabolites of melatonin may well contribute to the ability of the parent molecule to protect against oxidative stress. Because of this melatonin, rather than scavenging a single radical, may neutralize a number of toxic reactions via an antioxidant cascade\(^{55,56}\).

Different antioxidants have been tested in experimental liver fibrosis models to decrease oxidative damage. In a comparative study between the antioxidant protective effect of both melatonin and vitamin E, carried out by Montilla et al.\(^{26}\), they found that melatonin (at a much lower dose than vitamin E) was much more efficient than vitamin E in reducing the negative parameters of oxidative stress and provided a significantly greater hepatoprotective effect against the liver injury than did a much higher dose of vitamin E. Also, melatonin had a more potent effect in restoring antioxidative enzyme activities. They added that melatonin is an effective antioxidant and a free radical scavenger as it can cross biological membranes easily and reach all compartments within the cell due to
its small size and high lipophilicity. Also, Rozov et al.\(^{(57)}\) recorded that melatonin has a higher antioxidant efficiency than vitamin E and GSH, which are known as powerful antioxidants.

In the present study, hepatic damage induced by CCl\(_4\) administration was evaluated by measuring serum level of some of hepatic enzymes as alanine amino transferase (ALT) and aspartate aminotransferase (AST). Rats of CCl\(_4\) treated group (group II) showed significant increase of ALT and AST levels as compared to values of control group. After melatonin co-treatment to group III, a significant decrease of these hepatic enzymes was observed in all treated animals, which indicates that melatonin has a protective effect on hepatic cells after CCl\(_4\) intoxication. These findings were in agreement with other investigators, who recorded marked improvement of hepatic functions with reduction of hepatic enzymes by administration of melatonin to animals with CCl\(_4\) hepatic intoxication \(^{(12,58,59)}\). In 2008, Ogeturk et al.\(^{(60)}\) revealed that liver dysfunction after CCl\(_4\) intoxication caused marked increases in plasma ALT and AST activities. Also, Rasha et al. (2009)\(^{(10)}\) reported that a single dose of CCl\(_4\) induced hepatotoxicity manifested biochemically by significant elevation of activities of liver enzymes, such as ALT and AST. They added that there was marked reduction of hepatic enzyme activities after melatonin administration. In 2009, Hong et al.\(^{(7)}\) proved that melatonin administration to CCl\(_4\) treated rats (at a dose of 10 mg/kg) was effective in reducing serum ALT and AST levels, indicating that melatonin can protect liver and alleviate the progression of hepatic fibrosis.

In the current study, the fibrotic effect of CCl\(_4\) on hepatic tissues of group II rats was assessed by measuring serum level of hyaluronic acid (HA). It is well known that HA is a good serum marker of hepatic fibrogenesis even at its early stage \(^{(61,14)}\). So, it is considered a good marker for detection of initial phase of hepatic fibrosis which help in early diagnosis of hepatic fibrogenesis and able to assess severity of liver disease as mentioned by Kopk-Aguiar et al. (2002)\(^{(62)}\).

The result of the present study showed significant increase in serum level of HA in CCl\(_4\) treated group (group II) when compared to control group (group I). This increase in HA in the present study was in agreement with that of Mchutchison et al. (2000)\(^{(63)}\) who stated that there was an increase in serum levels of HA in patients with early phase of hepatic injury before developing of fibrosis or cirrhosis. Additionally, the current study revealed a significant positive correlation between serum levels of HA and hepatic enzymes (ALT&AST). These data were in agreement with the result of Xie et al. (2003)\(^{(64)}\) as they recorded that the concentrations of serum HA was positively correlated with the inflammatory activity and degrees of hepatic fibrosis and cirrhosis. Lu et al. (2003)\(^{(65)}\) stated that serum HA was correlated with the degree of hepatic inflammation and liver fibrosis stage and correlated with other liver function parameters.
including AST, ALT, albumin, A/G ratio and alkaline phosphatase (ALP).

This increase in serum level of HA in group II, 8 weeks after CCl₄ treatment could be explained by modulation of uptake and degradation of serum HA by the hepatic endothelial cells in this early reversible stage of hepatic fibrosis. Also, Patel et al. (2003) stated that in patients with fibrosis, the elevation of serum HA is believed to be the result of increased synthesis by activated stellate cells and decreased clearance by sinusoidal endothelial cells. Additionally, Abd-el-Fattah et al. (2006) explained that HA increases due to diminishing HA clearance by the cirrhotic liver cells and also hyaluronidase enzyme activity decreased proportionally to the severity of liver disorders.

The present study demonstrates partial protective effect of melatonin on hepatic fibrosis induced by CCl₄. Co-treatment of rats of group III with melatonin (at the dose of 20 mg/kg twice a week for 8 weeks), significantly reduced serum levels of HA as compared with the rats that received only CCl₄ (group II). This was in agreement with many previous studied who proved that melatonin could decrease hepatic fibrosis and serum HA levels in rats with hepatic injury caused by CCl₄. In 2009, Hong et al. recorded that; treatment with melatonin (10 mg/kg) could significantly reduce serum levels of HA. The decrease of serum HA level indicates that melatonin can inhibit collagen deposition in liver.

Previous reports have shown that the synthesis or metabolism of collagen is closely associated with melatonin. It was shown that melatonin has an inhibitory role on collagen accumulation with suppressing the pinealectomy-induced elevation of collagen content during wound healing. Other evidence suggested a relationship between primary biliary cirrhosis and melatonin deficiency because of the demonstration of increased pigmentation and accelerated fibrosis in pinealectomized rats. Also, in 2002, Arslan et al. proved that melatonin has therapeutic activities in bleomycin-induced pulmonary fibrosis.

An increase of oxidative stress markers production can play an important role in the formation of hepatic fibrosis via increasing stellate cell activation and collagen synthesis. It has been shown that MDA can activate stellate cells that produce collagen. Several lines of evidence suggest that melatonin plays an important role in regulation of collagen levels and inhibition of collagen accumulation. The results of the present study revealed that treatment with melatonin could significantly block increased LPO, suggesting that melatonin decreases oxidative stress via decreasing lipid peroxidation, so it can play an anti-fibrotic role in hepatic fibrosis induced by CCl₄ in rats. In 2005, Wang et al. proved that melatonin has an effective protective role against hepatic damage in a rat hepatic fibrosis model induced by a 6-weeks CCl₄ regimen. This protective action of melatonin might be related to its antioxidant activity and inhibition of proinflammatory cytokines production.
In 2006 Sigala et al.\(^{(73)}\) showed that products of lipid peroxidation can stimulate collagen gene expression in cultured fibroblasts and they proposed that lipid peroxidation could be a link between tissue injury and tissue fibrogenesis. From all the above studies, it can be speculated that early inhibition of lipid peroxidation by using a proper antioxidant as melatonin may be the most important mechanism of reducing liver fibrosis.

In the present study, liver injury was assessed with biochemical and histological parameters. Histopathological examination of liver specimens in the CCl\(_4\) treated rats (group II) showed that the liver structure was disrupted with dilated blood vessels, collagen deposition and more necrotic and fatty degenerated liver cells compared with the controls (figure 2). In group III (CCl\(_4\) + melatonin), histological study of hepatic tissues showed that melatonin could obviously attenuate the extent of necrosis and reduce the histological signs of liver damage and fibrosis (figure 3), documenting a significant protective effect of melatonin against liver damage and fibrosis caused by CCl\(_4\) injection. These findings are consistent with previously reported results\(^{(7,59,76,77)}\). In 2005, Wang et al.\(^{(58)}\) proved that melatonin at the dose of 10 or 20 mg/kg significantly reduced the scores of liver fibrosis, documenting a significant protective effect of melatonin on hepatic histology and inhibition of collagen deposition caused by hepatic intoxication. Additionally, in 2005, Zavodnik et al.\(^{(59)}\) stated that exposure to CCl\(_4\)-induced substantial morphological changes in rat liver with disruptions of hepatic structure including necrosis and fatty and hydropic dystrophy. Melatonin administration lowered the degree of necrosis and dystrophic changes in these rats. Also, in 2009, results of the study carried by Hong et al.\(^{(7)}\) suggested that melatonin could decrease the scores of hepatic fibrosis and serum ALT and AST levels in rats with hepatic injury caused by CCl\(_4\).

The present study revealed the hepatic protective effect of melatonin administration in case of CCl\(_4\)-hepatic toxicity. The study also explained different mechanisms of this protective effect of melatonin mainly through decreasing oxidative stress and restoring antioxidative enzymes as well as its anti-fibrotic effect. Another mechanism of melatonin hepatic protective effect may be due to its antiapoptotic effect as stated by Guha et al., in 2007\(^{(78)}\), but the exact mechanism of melatonin-provided prevention of hepatic apoptosis is not completely clear. Some investigators (Noyan et al., 2006 and Molpeceres et al., 2007)\(^{(18,79)}\) attributed the antiapoptotic effects of melatonin to its antioxidant and free radical scavenging activities. In 2008, Ogeturk et al.\(^{(60)}\) found that chronic administration of CCl\(_4\) induced apoptosis in the liver. Furthermore, they showed that melatonin substantially reduced CCl\(_4\)-induced apoptotic changes in rats. This antiapoptotic effect of melatonin was in agreement with other studies showing that melatonin diminishes apoptosis in endotoxemic intestinal injury (Ozdemir et al., 2007)\(^{(80)}\) and in formaldehyde-induced cortical
neurotoxicity (Zararsiz et al., 2007)\(^{(81)}\).

Andrabi et al. (2004)\(^{(82)}\) and Guha et al. (2007)\(^{(77)}\) showed that melatonin exerts its antiapoptotic action via direct inhibition of the mitochondrial permeability transition pore. In 2005, Esrefoglu et al.\(^{(83)}\) stated that melatonin significantly reduces cell death in tissues from both the necrotic and apoptotic pathways. Meki et al. 2001\(^{(84)}\) showed that in a rat liver injury caused by aflatoxin B1 (a toxin which leads to apoptosis) melatonin treatment of the rats reduced the apoptotic and necrobiotic changes in the liver. Additionally, Jou et al. (2004)\(^{(85)}\) showed that melatonin, readily rescued mitochondria from oxidative stress-induced dysfunction and effectively prevented subsequent apoptotic events and death in rat brain astrocytes. So, it seems that melatonin reinforces its therapeutic potential to combat a variety of oxidative stress-induced mitochondrial dysfunctions as well as mitochondria-mediated apoptosis in various diseases.

In conclusion, our study shows that melatonin, which is a safe molecule without relevant noxious side effects, has a substantial hepatoprotective effect in a rat hepatic fibrosis model induced by a 8-weeks’ CCl\(_4\) regimen. The results of the biochemical and histological measurements reported in this study proved that co-administration of melatonin with CCl\(_4\) was able to decreases oxidative stress, hepatic cell damage and liver fibrosis in rat liver during hepatic intoxication with CCl\(_4\). The protective effect of melatonin may be due to both its direct radical scavenging properties and indirect effects as a regulator of antioxidant systems. Therefore, the study proposes that melatonin may be a valuable drug for inhibition of unwanted fibrosis in patients exposed to different hepatotoxic agents.

Acknowledgments

The authors of this study thank Dr. Hemmat Hariedy, (Assistant Professor of Histology, Faculty of Medicine, Assuit University) for her excellent histological assistance and her kindly help.

REFERENCES


60- Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. (2006): Hyaluronic acid levels can predict severe
fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol., 21: 1459-1465.


تأثير الميلاتونين الوقائي من حدوث تليف الكبد المستحدث في الفئران باستخدام رباعي كلورويد الكربون (CCL4)

العنوان:

تأثير الميلاتونين الوقائي من حدوث تليف الكبد المستحدث في الفئران باستخدام رباعي كلورويد الكربون (CCL4)

خليفة البحث: تليف الكبد هو مرحلة حرجة من أمراض الكبد المزمنة يمكن أن يؤدي إلى شلل الكبد، ارتفاع ضغط الشريان البولي وسرطان الكبد. يلعب استمرار ووجود العناصر المؤكسدة دوراً رئيسياً في تلك الخلايا وحث التليف الكبد.)

هدف هذه الدراسة: تهدف هذه الدراسة إلى اختبار التأثير الوقائي المحتمل لتطبيق الميلاتونين كعلاج مساعد لمنع تليف الكبد الناجم عن تلف الفئران برابع كلورويد الكربون (CCL4)

الطريقة: في هذه الدراسة تم إعداد نماذج للفئران برابع كلورويد الكربون بعد 16 من ادغام الفئران باللفة، تم قسم الفئران عشوائياً إلى ثلاث مجموعات (ن=3)

- المجموعة الأولى: المجموعة الضبابية، المجموعة الضبابية، المجموعة الضبابية، المجموعة الضبابية، المجموعة الضبابية، المجموعة الضبابية

- المجموعة الثانية: المجموعة الضبابية، المجموعة الضبابية، المجموعة الضبابية، المجموعة الضبابية، المجموعة الضبابية، المجموعة الضبابية

- المجموعة الثالثة: المجموعة الضبابية، المجموعة الضبابية، المجموعة الضبابية، المجموعة الضبابية، المجموعة الضبابية، المجموعة الضبابية

وبعد 81 يوم عن طريق حقن مزيج من NO & LPO (CCL4)

النتائج: أظهرت هذه الدراسة أن تليف الكبد المزمن في الفئران على نمط CCL4 هو يتمتع بالوقاية المحتملة للفئران من حدوث تليف الكبد الناجم عن تلف الفئران برابع كلورويد الكربون.

الاستنتاج: تلخيص هذه الدراسة في نتائجها التي تظهر أن الميلاتونين يمكن أن يكون حماة للكبد من تلف الكبد الناجم عن تلف الفئران برابع كلورويد الكربون.